However, ERα-positive breast cancer patients exhibit improved overall survival (OS) compared to ERα-negative patients, likely owing to the clinical benefit of adjuvant endocrine therapies for ERα-positive patients [18,29]. This evidence concerns the gene ESR1 and breast carcinoma.